Ovid Therapeutics to Present at Upcoming September Investor Conferences
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on rare epilepsies and brain conditions, has announced its participation in two major investor conferences this September. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET. Additionally, Ovid will engage in a fireside chat at the Cantor Global Healthcare Conference on September 17th at 1:55 p.m. ET.
Both events will be webcast live and can be accessed through the Events & Presentations section of Ovid's investor website. Archived replays will be available on the company's website following the live presentations, providing investors and interested parties with opportunities to stay informed about Ovid's latest developments and strategic outlook.
Ovid Therapeutics (NASDAQ: OVID), un'azienda biofarmaceutica focalizzata su epilessie rare e condizioni cerebrali, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo settembre. L'azienda presenterà al 26° Convegno Globale Annuale di Investimenti H.C. Wainwright il 10 settembre alle 15:30 ET. Inoltre, Ovid parteciperà a un fireside chat alla Conferenza Globale Sanitaria di Cantor il 17 settembre alle 13:55 ET.
Entrambi gli eventi saranno trasmessi in diretta e saranno accessibili attraverso la sezione Eventi & Presentazioni del sito web per investitori di Ovid. Le registrazioni archiviate saranno disponibili sul sito dell'azienda dopo le presentazioni dal vivo, offrendo agli investitori e agli interessati opportunità di rimanere aggiornati sugli ultimi sviluppi e sulle prospettive strategiche di Ovid.
Ovid Therapeutics (NASDAQ: OVID), una compañía biofarmacéutica centrada en epilepsias raras y condiciones cerebrales, ha anunciado su participación en dos importantes conferencias de inversores este septiembre. La empresa presentará en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright el 10 de septiembre a las 3:30 p.m. ET. Además, Ovid participará en un fireside chat en la Conferencia Global de Salud de Cantor el 17 de septiembre a la 1:55 p.m. ET.
Ambos eventos serán transmitidos en vivo y se podrán acceder a través de la sección de Eventos y Presentaciones en el sitio web para inversores de Ovid. Las grabaciones archivadas estarán disponibles en el sitio de la compañía tras las presentaciones en vivo, brindando a los inversores y partes interesadas oportunidades para mantenerse informados sobre los últimos desarrollos y la perspectiva estratégica de Ovid.
Ovid Therapeutics (NASDAQ: OVID) 는 희귀 간질 및 뇌질환에 집중하는 생명공학 회사로, 이번 9월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 9월 10일 오후 3시 30분 ET에 H.C. Wainwright 제26회 글로벌 투자 회의에서 발표할 예정입니다. 또한 Ovid는 9월 17일 오후 1시 55분 ET에 Cantor 글로벌 헬스케어 회의에서 파이어사이드 챗에 참여합니다.
두 이벤트 모두 생중계될 예정이며 Ovid의 투자자 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 접근할 수 있습니다. 보관된 재생은 라이브 프레젠테이션 이후 회사 웹사이트에서 제공되어, 투자자와 관심 있는 사람들이 Ovid의 최신 개발 및 전략적 전망에 대해 정보를 유지할 수 있는 기회를 제공합니다.
Ovid Therapeutics (NASDAQ: OVID), une entreprise biopharmaceutique axée sur les épilepsies rares et les troubles du cerveau, a annoncé sa participation à deux grandes conférences d'investisseurs en septembre. L'entreprise présentera à la 26e Conférence Annuelle Globale d'Investissement H.C. Wainwright le 10 septembre à 15h30 ET. De plus, Ovid participera à un fireside chat à la Conférence Sanitaire Globale de Cantor le 17 septembre à 13h55 ET.
Les deux événements seront diffusés en direct et accessibles via la section Événements et Présentations du site web des investisseurs d'Ovid. Des rediffusions archivées seront disponibles sur le site de l'entreprise après les présentations en direct, permettant aux investisseurs et aux parties intéressées de rester informés sur les derniers développements et les perspectives stratégiques d'Ovid.
Ovid Therapeutics (NASDAQ: OVID), ein biopharmazeutisches Unternehmen, das sich auf seltene Epilepsien und Erkrankungen des Gehirns konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September bekannt gegeben. Das Unternehmen wird am 10. September um 15:30 Uhr ET auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright präsentieren. Darüber hinaus wird Ovid am 17. September um 13:55 Uhr ET an einem Fireside Chat auf der Cantor Global Healthcare Conference teilnehmen.
Beide Veranstaltungen werden live übertragen und sind über den Bereich Veranstaltungen & Präsentationen auf der Investoren-Website von Ovid zugänglich. Archivierte Aufzeichnungen werden nach den Live-Präsentationen auf der Website des Unternehmens verfügbar sein und den Investoren und Interessierten die Möglichkeit bieten, über die neuesten Entwicklungen und strategischen Aussichten von Ovid informiert zu bleiben.
- None.
- None.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in September:
- H.C. Wainwright 26th Annual Global Investment Conference – Ovid will present on September 10th at 3:30 p.m. ET.
- Cantor Global Healthcare Conference – Ovid will participate in a fireside chat on Tuesday, September 17th at 1:55 p.m. ET.
Live webcasts of the fireside chat and presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations:
Garret Bonney
617-735-6093
gbonney@ovidrx.com
FAQ
When is Ovid Therapeutics presenting at the H.C. Wainwright Global Investment Conference?
What is the date and time of Ovid Therapeutics' fireside chat at the Cantor Global Healthcare Conference?
How can investors access Ovid Therapeutics' presentations at the September conferences?
What is the focus of Ovid Therapeutics as a biopharmaceutical company?
